Y. Toi, “Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study: BSA and nintedanib reduction/discontinuation”, Sarcoidosis Vasc Diffuse Lung Dis, vol. 36, no. 1, pp. 74–78, Mar. 2019, doi: 10.36141/svdld.v36i1.7383.